Inovio Pharma (INO) Updates on INO-3112 HPV Plans; EORTC Trial Study Will Not Move Forward (AZN)
Tweet Send to a Friend
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced a clinical strategy update to take its INO-3112 HPV immunotherapy into human studies in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
